CPP (Cancer Prevention Pharmaceuticals) Price-to-Owner-Earnings : (As of Apr. 26, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Price-to-Owner-Earnings?

As of today (2025-04-26), Cancer Prevention Pharmaceuticals's share price is $25.91. Cancer Prevention Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

CPP's Price-to-Owner-Earnings is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 24.01
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-26), Cancer Prevention Pharmaceuticals's share price is $25.91. Cancer Prevention Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.97. Therefore, Cancer Prevention Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-26), Cancer Prevention Pharmaceuticals's share price is $25.91. Cancer Prevention Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.40. Therefore, Cancer Prevention Pharmaceuticals's PE Ratio without NRI for today is At Loss.

Cancer Prevention Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Price-to-Owner-Earnings Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Price-to-Owner-Earnings

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Price-to-Owner-Earnings	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings falls into.

Save Embed

;

Save Embed

;

Cancer Prevention Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	25.91	/	0.00
	=

Cancer Prevention Pharmaceuticals (AMEX:CPP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Cancer Prevention Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.